AMENDED AND RESTATED SERVICES AGREEMENTServices Agreement • July 13th, 2018 • Urovant Sciences Ltd. • Pharmaceutical preparations • New York
This Amended and Restated Services Agreement (the “Agreement”) is entered into effective as of July 9 2018, by and among Roivant Sciences, Inc., a corporation organized under the laws of the State of Delaware (the “Service Provider”), Urovant Sciences GmbH (f/k/a Thalavant Sciences GmbH), a company with limited liability organized under the laws of Switzerland (“USG”), Urovant Sciences, Inc. (f/k/a Thalavant Sciences, Inc.), a corporation organized under the laws of the State of Delaware (“USI”), and Urovant Sciences Ltd. (f/k/a Thalavant Sciences Ltd.), an exempted limited company organized under the laws of Bermuda (“USL”, and together with USI and USG, and any Additional Service Recipient the “Service Recipients” and each a “Service Recipient”).
INFORMATION SHARING AND COOPERATION AGREEMENT by and among UROVANT SCIENCES LTD., AND ROIVANT SCIENCES LTD. Dated as of July 9, 2018Information Sharing and Cooperation Agreement • July 13th, 2018 • Urovant Sciences Ltd. • Pharmaceutical preparations • New York
This INFORMATION SHARING AND COOPERATION AGREEMENT (this “Agreement”), dated as of July 9, 2018 (the “Effective Date”), is entered into between Urovant Sciences Ltd., a Bermuda exempted limited company (the “Company”) and Roivant Sciences Ltd., a Bermuda exempted limited company (“Roivant”), (with each of the Company and Roivant, a “Party” and together, the “Parties”).
DATA SHARING AGREEMENTData Sharing Agreement • July 13th, 2018 • Urovant Sciences Ltd. • Pharmaceutical preparations • California
This Data Sharing Agreement (this “Agreement”) is entered into effective as of May 22, 2018 (the “Effective Date”), by and between Urovant Sciences GmbH, a limited liability company organized under the laws of Switzerland (“Urovant GmbH”), and Datavant, Inc., a company organized under the laws of the State of Delaware (“Datavant”). Urovant GmbH and Datavant are referred to individually as a “Party” and collectively as the “Parties.”
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 13th, 2018 • Urovant Sciences Ltd. • Pharmaceutical preparations • Delaware
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of July 7, 2018 by and among Urovant Sciences Ltd., an exempted limited company incorporated under the laws of Bermuda (the “Company”), and Roivant Sciences Ltd. (“RSL”).
LICENSE AGREEMENT by and between MERCK SHARP & DOHME CORP. and UROVANT SCIENCES GMBHLicense Agreement • July 13th, 2018 • Urovant Sciences Ltd. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (this “Agreement”) is made and entered into this February 3, 2017 (the “Effective Date”), by and between Merck Sharp & Dohme Corp. a corporation organized and existing under the laws of the State of New Jersey (“Merck”), and Urovant Sciences GmbH (“Urovant”), a company organized and existing pursuant to the laws of Switzerland, [***]. Merck and Urovant are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
COLLABORATION AGREEMENTCollaboration Agreement • July 13th, 2018 • Urovant Sciences Ltd. • Pharmaceutical preparations • New York
THIS COLLABORATION AGREEMENT (this “Agreement”) is made and entered into this 1st of June, 2018 (the “Effective Date”), by and between Urovant Sciences GmbH (“Urovant”), a Switzerland limited liability company with an address of 8 Viaduktstrasse, 4051 Basel, Switzerland, and Roivant Sciences GmbH (“Roivant”), a Switzerland limited liability company with an address of 8 Viaduktstrasse, 4051 Basel, Switzerland. Urovant and Roivant are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
CHINA IP PURCHASE AGREEMENTIp Purchase Agreement • July 13th, 2018 • Urovant Sciences Ltd. • Pharmaceutical preparations
This CHINA IP PURCHASE AGREEMENT (this “Agreement”) is made and entered into this 12th day of June, 2017 (“Effective Date”), by and between Urovant Sciences GmbH, a Switzerland limited liability company with an address of do Vischer AG, Aeschenvorstadt 4, CH-4010 Basel, Switzerland (“Seller”), and Roivant Sciences GmbH, a Switzerland limited liability company with an address of c/o Vischer AG, Aeschenvorstadt 4, CH-4010 Basel, Switzerland (“Buyer”). Each of the Seller and the Buyer are referred to in this Agreement as a “party” and together as the “parties”.
ENZYME SUPPLY AGREEMENTEnzyme Supply Agreement • July 13th, 2018 • Urovant Sciences Ltd. • Pharmaceutical preparations • New York
THIS ENZYME SUPPLY AGREEMENT, including the exhibits attached hereto (the “Agreement”), effective as of September 01, 2017 (the “Effective Date”), is made and entered into by and between Codexis, Inc., a Delaware corporation, having a place of business at 200 Penobscot Drive, Redwood City, California 94063, United States of America (“Codexis”), and Urovant Sciences GmbH, a Swiss corporation, having a place of business at Viaduktstrasse 8, 4051 Basel, Switzerland (“Customer”). Codexis and Customer each may be referred to herein individually as a “Party,” or collectively as the “Parties.”
COLLABORATION AGREEMENT by and between UROVANT SCIENCES GMBH and KYORIN PHARMACEUTICAL CO., LTD. Dated as of August 24, 2017Collaboration Agreement • July 13th, 2018 • Urovant Sciences Ltd. • Pharmaceutical preparations
This Collaboration Agreement (this “Agreement”) dated August 24, 2017 (“Effective Date”), is by and between Urovant Sciences GmbH, having a place of business at Viaduktstrasse 8, 4051 Basel, Switzerland (“Urovant”), and Kyorin Pharmaceutical Co., Ltd., having a place of business at 6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo 101-8311, Japan (“Kyorin”).
